Overview

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Status:
Completed

Trial end date:
2009-05-11

Target enrollment:

Participant gender:

Summary

This is a study to determine the safety and tolerability of 28 days of daily dosing of two doses (280 mg and 560 mg) of Arikayce™ versus placebo in patients who have bronchiectasis and chronic infection due to Pseudomonas infection.

Phase:

Phase 2

Details

Lead Sponsor:

Insmed Incorporated

Treatments:

Amikacin